ଆମିଭାଣ୍ଟାମାବ

ଆମିଭାଣ୍ଟାମାବ
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Epidermal growth factor receptor (EGFR) and Mesenchymal–epithelial transition (MET)
Clinical data
Trade names	Rybrevant
Synonyms	JNJ-61186372, amivantamab-vmjw
AHFS/Drugs.com	monograph
data	US DailyMed: Amivantamab;
Routes of; administration	Intravenous infusion
Legal status
Legal status	CA: ℞-only / Schedule D; US: ℞-only ; EU: Rx-only ;
Chemical and physical data
Formula	C6472H10014N1730O2023S46
Molar mass	୧,୪୫,୯୦୨.୧୫ g·mol−1

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Amivantamab

ଆମିଭାଣ୍ଟାମାବ (ଇଂରାଜୀ ଭାଷାରେ Amivantamab), ରାଇବ୍ରେଭାଣ୍ଟ ଏହାର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଅଣ-ଛୋଟ କୋଷ ଫୁସଫୁସ କର୍କଟ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୪] ^[୩] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଆଗେଇ ଯାଇଥିବା ଏପିଡର୍ମାଲ୍ ଅଭିବୃଦ୍ଧି ଫ୍ୟାକ୍ଟର୍ ରିସେପ୍ଟର (EGFR) ଏକ୍ସନ୍ ୨୦ ଇନସର୍ସନ ମ୍ୟୁଟେସନ ଥିଲେ ଏହା ବ୍ୟବହୃତ ହୁଏ, ଯେତେବେଳେ ଅନ୍ୟ ଚିକିତ୍ସାରେ ବିଫଳ ହୋଇଥାଏ ।^[୪] ଏହା ଏକ ଶିରାରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ରାସ, ଇନଫ୍ୟୁଜନ୍ ପ୍ରତିକ୍ରିୟା, ନଖ ଚାରିପାଖରେ ସଂକ୍ରମଣ, ମାଂସପେଶୀ ଏବଂ ଗଣ୍ଠି ଯନ୍ତ୍ରଣା, ଅଣନିଶ୍ୱାସ, ବାନ୍ତି, ଥକାପଣ, ଫୁଲା, ପାଟିରେ ଘା’, କାଶ ଏବଂ କୋଷ୍ଠକାଠିନ୍ୟ ହୋଇପାରେ ।^[୪] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିମୋନାଇଟିସ, ଆଖି ସମସ୍ୟା, କମ୍ ରକ୍ତ ପୋଟାସିୟମ୍ ବା ହାଇପୋକାଲେମିଆ, ଉଚ୍ଚ ରକ୍ତ ଶର୍କରା, ଅଳ୍ପ ସୋଡିଅମ୍ ରକ୍ତ‌ତା ଏବଂ ଯକୃତ ପ୍ରଦାହ ହୋଇପାରେ ।^[୪] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୪] ଏହା ଏକ ଦ୍ୱିପାକ୍ଷିକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ଏପିଡର୍ମାଲ୍ ବୃଦ୍ଧି ଫ୍ୟାକ୍ଟର୍ (EGF) ରିସେପ୍ଟର ଏବଂ ମେସେନ‌କାଇମାଲ- ଏପିଥେଲିଆଲ ଟ୍ରାଞ୍ଜିସନ (MET) ରିସେପ୍ଟର ସହିତ ସଂଲଗ୍ନ ହୁଏ ।^[୪]

୨୦୨୧ ମସିହାରେ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଆମିଭାଣ୍ଟାମାବ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୪] ^[୩] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୨ ସୁଦ୍ଧା ଏକ ୩୫୦ ମିଗ୍ରା ଭାଏଲର ମୂଲ୍ୟ ୧୧୦୦ ପାଉଣ୍ଡ ଥିଲା ।^[୭] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୩୫୦୦ ଡଲାର ଅଟେ ।^[୮]

ଆଧାର[ସମ୍ପାଦନା]

↑ "Rybrevant Product information". Health Canada. 25 April 2012. Archived from the original on 29 June 2022. Retrieved 29 June 2022.
↑ "Summary Basis of Decision - Rybrevant". Health Canada. 23 October 2014. Archived from the original on 6 August 2022. Retrieved 6 August 2022.
↑ ^୩.୦ ^୩.୧ ^୩.୨ "Rybrevant EPAR". European Medicines Agency (EMA). 12 October 2021. Archived from the original on 23 April 2022. Retrieved 23 April 2022. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ ^୪.୭ ^୪.୮ "Rybrevant- amivantamab injection". DailyMed. Janssen Pharmaceutical Companies. Archived from the original on 26 May 2021. Retrieved 25 May 2021.
↑ "FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer". U.S. Food and Drug Administration (FDA) (Press release). 21 May 2021. Archived from the original on 21 May 2021. Retrieved 21 May 2021. This article incorporates text from this source, which is in the public domain.
↑ "FDA grants accelerated approval to amivantamab-vmjw for mNSCLC". U.S. Food and Drug Administration (FDA). 21 May 2021. Archived from the original on 22 May 2021. Retrieved 21 May 2021. This article incorporates text from this source, which is in the public domain.
↑ "Amivantamab". SPS - Specialist Pharmacy Service. 9 December 2020. Archived from the original on 2 March 2022. Retrieved 29 October 2022.
↑ "Rybrevant Prices, Coupons, Copay & Patient Assistance". Drugs.com (in ଇଂରାଜୀ). Retrieved 29 October 2022.

[1] "Rybrevant Product information". Health Canada. 25 April 2012. Archived from the original on 29 June 2022. Retrieved 29 June 2022.

[2] "Summary Basis of Decision - Rybrevant". Health Canada. 23 October 2014. Archived from the original on 6 August 2022. Retrieved 6 August 2022.

[EPAR2022-3] ୩.୦ ^୩.୧ ^୩.୨ "Rybrevant EPAR". European Medicines Agency (EMA). 12 October 2021. Archived from the original on 23 April 2022. Retrieved 23 April 2022. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[PI2022-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ ^୪.୭ ^୪.୮ "Rybrevant- amivantamab injection". DailyMed. Janssen Pharmaceutical Companies. Archived from the original on 26 May 2021. Retrieved 25 May 2021.

[FDA_PR_20210521-5] "FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer". U.S. Food and Drug Administration (FDA) (Press release). 21 May 2021. Archived from the original on 21 May 2021. Retrieved 21 May 2021. This article incorporates text from this source, which is in the public domain.

[FDA_amivantamab-6] "FDA grants accelerated approval to amivantamab-vmjw for mNSCLC". U.S. Food and Drug Administration (FDA). 21 May 2021. Archived from the original on 22 May 2021. Retrieved 21 May 2021. This article incorporates text from this source, which is in the public domain.

[SPS2022-7] "Amivantamab". SPS - Specialist Pharmacy Service. 9 December 2020. Archived from the original on 2 March 2022. Retrieved 29 October 2022.

[8] "Rybrevant Prices, Coupons, Copay & Patient Assistance". Drugs.com (in ଇଂରାଜୀ). Retrieved 29 October 2022.

[୧]

[୨]

[୪]

[୫]

[୬]

[୩]

[୭]

[୮]